Targeting the NOTCH1 signaling pathway may be crucial to treating relapsed and resistant T-ALL, since NOTCH1 gene mutations are important oncogenes in T-ALL [39]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.